Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21988041 | 0.87 | STING1 (0.59) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL22049377 | 0.86 | STING1 (0.58) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL22049592 | 0.86 | STING1 (0.61) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL30885403 | 0.86 | BRAF (0.52) | STING1BRAFTRPV1RAB9A | |
| SCHEMBL21988104 | 0.84 | STING1 (0.55) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL22049376 | 0.84 | AAK1 (0.64) | STING1BRAFAAK1TRPV1RIPK1 | |
| SCHEMBL21988113 | 0.84 | STING1 (0.55) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL22049581 | 0.84 | STING1 (0.55) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL21988120 | 0.84 | STING1 (0.55) | STING1BRAFEPHX2AAK1TRPV1 | |
| SCHEMBL22049748 | 0.84 | STING1 (0.55) | STING1BRAFEPHX2AAK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004785-A | Compounds and compositions for the treatment of diseases associated with STING activity | 诺华制药股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-112823036-B | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| WO-2022140403-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140387-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140397-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140410-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-112823036-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2021-05-18 | — | — | CN | disclosed |
| EP-3817820-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172534-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885BRAF 369/4885EPHX2 1579/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | STING1 1/4885BRAF 884/4885EPHX2 2928/4885 |
| US-11618749-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, IRF3, CGAS | STING1 1/4885BRAF 378/4885EPHX2 1315/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885BRAF 369/4885EPHX2 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.